• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CorMedix Inc.

    2/13/24 5:02:29 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRMD alert in real time by email
    SC 13G 1 tv0685-cormedixinc.htm SCHEDULE 13G cormedixinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  CorMedix Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  21900C308

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  21900C308

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    85,309

    7.  SOLE DISPOSITIVE POWER

    2,715,990

    8.  SHARED DISPOSITIVE POWER

    109,345

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,825,335

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.15%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    CorMedix Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    300 Connell Drive, Suite 4200
    Berkeley Heights, NJ 07922

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    21900C308

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CRMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRMD

    DatePrice TargetRatingAnalyst
    6/30/2025Buy → Hold
    D. Boral Capital
    6/30/2025$20.00Buy
    H.C. Wainwright
    3/7/2025$18.00Outperform
    Leerink Partners
    1/13/2025$15.00Buy
    D. Boral Capital
    8/26/2024$13.00Buy
    Rodman & Renshaw
    8/10/2023$6.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cormedix downgraded by D. Boral Capital

    D. Boral Capital downgraded Cormedix from Buy to Hold

    6/30/25 8:42:52 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Cormedix with a new price target

    H.C. Wainwright initiated coverage of Cormedix with a rating of Buy and set a new price target of $20.00

    6/30/25 8:34:13 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Cormedix with a new price target

    Leerink Partners initiated coverage of Cormedix with a rating of Outperform and set a new price target of $18.00

    3/7/25 7:21:39 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

    CorMedix to pay Melinta $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders The agreement also includes a regulatory milestone payment of up to $25 million and royalties Transformational deal that strengthens and diversifies commercial product portfolio for CorMedix Melinta Therapeutics, LLC ("Melinta"), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announces that it has entered into a definitive agreement to be acquired by CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therap

    8/7/25 7:10:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

    ‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD) today announced financial results for the second quarter and six months ended June 30, 2025 and provided an update on its business announcing the acquisition of Melinta Therapeutics LLC, with a target closing date as early as September 1, 2025. Second Quarter and Six Months 2025 Financial Highlights For the second quarter of 2025, CorMedix recorded $39.7 million in net revenue from sales of De

    8/7/25 7:00:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

    Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potentialTransaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 millionPro forma 2025 combined revenues estimated to be $305 to $335 millionAdvances CorMedix's strategy to build a formidable specialty pharmaceutical business through a combination of organic and inorganic growthDynamic platform can be leveraged to support additional products and expand as the combined company enters its next ph

    8/7/25 7:00:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lefkowitz Steven W exercised 20,000 shares at a strike of $4.03, increasing direct ownership by 20% to 120,498 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    4/3/25 4:30:05 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Todisco Joseph exercised 59,170 shares at a strike of $3.38, increasing direct ownership by 13% to 530,721 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    4/2/25 7:00:03 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Todisco Joseph was granted 187,500 shares and covered exercise/tax liability with 23,977 shares, increasing direct ownership by 53% to 471,551 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    1/22/25 9:11:40 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    SEC Filings

    View All

    CorMedix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - CorMedix Inc. (0001410098) (Filer)

    8/12/25 4:43:37 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by CorMedix Inc.

    10-Q - CorMedix Inc. (0001410098) (Filer)

    8/7/25 8:51:30 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events

    8-K - CorMedix Inc. (0001410098) (Filer)

    8/7/25 7:31:26 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Commercial Officer Mistry Erin bought $14,985 worth of shares (1,500 units at $9.99), increasing direct ownership by 3% to 52,011 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    12/13/24 4:15:22 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    3/14/24 8:45:21 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    12/18/23 4:47:41 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

    SC 13G/A - CorMedix Inc. (0001410098) (Subject)

    11/14/24 4:34:05 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

    SC 13G/A - CorMedix Inc. (0001410098) (Subject)

    2/14/24 10:37:21 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CorMedix Inc.

    SC 13G - CorMedix Inc. (0001410098) (Subject)

    2/13/24 5:02:29 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Financials

    Live finance-specific insights

    View All

    Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

    ‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD) today announced financial results for the second quarter and six months ended June 30, 2025 and provided an update on its business announcing the acquisition of Melinta Therapeutics LLC, with a target closing date as early as September 1, 2025. Second Quarter and Six Months 2025 Financial Highlights For the second quarter of 2025, CorMedix recorded $39.7 million in net revenue from sales of De

    8/7/25 7:00:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

    Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potentialTransaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 millionPro forma 2025 combined revenues estimated to be $305 to $335 millionAdvances CorMedix's strategy to build a formidable specialty pharmaceutical business through a combination of organic and inorganic growthDynamic platform can be leveraged to support additional products and expand as the combined company enters its next ph

    8/7/25 7:00:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

    ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys

    5/6/25 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Leadership Updates

    Live Leadership Updates

    View All

    CorMedix Inc. Announces Appointment of Chief Legal Officer

    BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has

    12/15/23 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Announces Partnership With The Leapfrog Group

    – CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea

    12/4/23 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

    BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors. Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent. "We are pleased to welcome Rob Stewart to the CorMedix Board," said Joseph Todisco, Chief Executive Officer of CorMedix. "Rob's deep experience in global pharmaceutical management and broad professional network in the pharma space will be inval

    4/17/23 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care